



Supplementary Figure 4 Western blots indicate unidirectional dose-dependent decrease of ADMA and increase of SDMA (70KDa) with type I PRMT inhibitor MS023, but not type II inhibitor, GSK591. **Ai)** ADMA reduction in GBM lysates treated with type I PRMT inhibitor, MS023 at 1 μ M and 100 μ M. **ii)** No ADMA reduction with type II PRMT inhibitor with GSK591; **iii)** Dose-dependent increase in SDMA of protein at 70KDa upon type PRMT inhibition with 1 μ M and 100 μ M MS023; **iv)** Dose-dependent decrease of SDMA with 1 μ M and 100 μ M type II PRMT inhibitor, GSK591. **B)** Western blot of GBM patient samples treated with and without MS023 showing changes in ADMA (green arrows). ADMA is decreased following 100 nM MS023 for 192 hr in 4 out of 9 GBM lysates.